Intratympanic dexamethasone injection for refractory sudden sensorineural hearing loss
Intratympanic dexamethasone injection for refractory sudden sensorineural hearing loss
复制标题
DOI：
10.1097/01.mlg.0000205183.29986.f6
复制
发表时间：
2006-05-01
期刊：
影响因子：
2.6
通讯作者：
Cho, MJ
中科院分区：
文献类型：
--
作者：
Choung, YH;Park, K;Cho, MJ
目的：本病例对照研究旨在分析鼓室内地塞米松注射（ITDI）作为突发性感音神经性听力损失（SSNHL）患者经典口服类固醇治疗难治性的治疗选择的效果。方法：本研究纳入66例口服类固醇治疗难治性SSNHL患者。从2002年8月至2004年1月，我们对连续33例（34耳）患者进行ITDI前瞻性治疗。然后，我们回顾性地收集了年龄和性别匹配的先前患者的数据，这些患者在2000年3月至2002年7月的初始方案后没有再接受任何治疗。在2周的时间里，在仰卧位上进行了4次ITDI。在每次注射前和治疗后1周立即评估听力。听力改善定义为纯音平均（PTA）超过10 dB。结果。33例接受ITDI治疗的患者中有13例（39.4%）听力改善，对照组中有2例（6.1%）听力改善。13名患者中有5名PTA听力改善超过20 dB， 20名患者中有11名在某些频率的PTA改善超过10 dB。对ITDI有反应的患者和对ITDI没有反应的患者之间没有明确的预后因素。结论：ITDI治疗难治性SSNHL可能是一种简单有效的治疗方法。
Objective: This case-control study aimed to analyze the effect of intratympanic dexamethasone injection (ITDI) as a treatment option for patients with sudden sensorineural hearing loss (SSNHL) who were refractory to classic oral steroid treatment. Methods: Sixty-six patients with SSNHL, who were refractory to a course of oral steroid therapy, were included in this study. We prospectively treated consecutive 33 patients (34 ears) with ITDI from August 2002 to January 2004. We then retrospectively collected data from age- and sex-matched previous patients who did not take any more treatments after the initial regimen between March 2000 and July 2002. ITDI was performed in the supine position on four separate occasions over the course of 2 weeks. Hearing was assessed immediately before every injection and at I week after therapy. Hearing improvement was defined as more than 10 dB in pure-tone average (PTA). Results. Hearing improvement was observed in 13 (39.4%) of 33 patients who underwent ITDI and in two (6.1%) of 33 patients in the control group. Five of 13 represented hearing improvement over than 20 dB in PTA, and 11 of 20 patients, who showed no improvement in PTA by ITDI, showed improvement over 10 dB in some frequencies. There were no definite prognostic factors between the patients who responded to ITDI and those who did not. Conclusion: ITDI may be a simple and effective therapy for patients with refractory SSNHL.